IL6 and neoplasm: Accordingly, ruxolitinib treatment impaired a well‐described autocrine oncogenic activation loop in this model.10 Indeed, tumor cell‐derived expression of pro‐inflammatory cytokines IL‐6 and IL‐1β was significantly decreased in the ruxolitinib treated group, as verified by quantitative real‐time PCR using primers specific for the human transcripts of these cytokines (Fig. 2f).